Friday, August 7, 2026 · Covering: Mon–Fri this week
TL;DR
Healthcare M&A roared back on Monday with a "three deals in one day" burst: Curium agreed to merge with Lantheus in a ~$8B radiopharmaceutical tie-up and KKR agreed to take medtech supplier Integer private for $5.7B, even as a separate AstraZeneca megamerger was blocked. Equities ripped to record highs — the Dow, S&P 500 and Nasdaq all set all-time highs early in the week — powered by an 84%+ earnings-beat rate and standouts like Palantir and Caterpillar. The overhang: a new tariff schedule (rates from 10% to 40%+) took effect August 7, injecting fresh supply-chain and margin uncertainty just as the Fed holds rates at 3.50–3.75%.
TOP 3 DEALS
DEAL 01
Healthcare · Radiopharma
TRANSACTION VALUEUp to ~$8B
STRUCTUREMerger (cash + earnout components)
LANTHEUS ADVISERSMorgan Stanley (lead), BofA, Solomon Partners
CURIUM ADVISERSJefferies (lead), J.P. Morgan, PJT Partners
France-based Curium, one of Europe's largest radiopharmaceutical makers, agreed to combine with US-listed Lantheus to create a global leader in diagnostic and therapeutic radiopharmaceuticals — drugs that use radioactive isotopes to image and treat disease. The tie-up bulks up scale in one of the fastest-growing corners of oncology.
Why it matters for recruiting: Radiopharma is a hot subsector — note the deep bench of banks (three per side), signaling a hard-fought, high-fee process. It's a great "why is this sector consolidating?" talking point: manufacturing/supply-chain complexity and short isotope half-lives reward scale, which drives M&A.
DEAL 02
Medtech · LBO / Take-Private
ENTERPRISE VALUE~$5.7B (all-cash)
BUYERKKR (take-private)
KKR ADVISERSCenterview, Barclays, Citi, Raymond James
INTEGER ADVISERGoldman Sachs (exclusive)
KKR agreed to buy Integer Holdings, a contract manufacturer of components for medical devices (cardiac, neuro, and more), in an all-cash take-private. Integer is a "picks-and-shovels" supplier to the medtech industry — steady, diversified demand that lends itself to a leveraged buyout.
Why it matters for recruiting: A clean sponsor LBO of an outsourced-manufacturing platform. Be ready to explain why sponsors like recurring, contract-based revenue (predictable cash flows support debt), and note KKR's four-bank advisory/financing syndicate versus Integer's single exclusive adviser — a common asymmetry between sell-side and buy-side.
DEAL 03
Defense / Space · Carve-Out
TRANSACTION VALUEUndisclosed (majority stake)
BUYERAE Industrial Partners (PE)
SELLERL3Harris Technologies
ADVISERSAdvisers TBD
L3Harris closed the sale of a majority interest in its commercial space propulsion, power and electronics businesses to defense-focused PE firm AE Industrial Partners. The prime contractor is trimming non-core commercial lines to concentrate on its higher-priority defense mission areas.
Why it matters for recruiting: A defense carve-out to a sector specialist — a live example of portfolio pruning by a prime. Good fodder for A&D coverage: why primes divest commercial/space assets to sharpen focus, and why defense-dedicated sponsors pay up for propulsion IP amid record missile/satellite demand.
SECTOR SIGNAL
DEFENSE / AEROSPACE
The Pentagon signed 2 multiyear framework agreements worth $3B+ with Northrop Grumman and Lockheed Martin to expand solid-rocket-motor and structural output for PAC-3 and THAAD interceptors — a demand signal for the whole munitions supply chain. GlobalSecurity ↗
TECH / TMT
Palantir led earnings-season standouts, helping push the Nasdaq to record highs; AI-linked names continue to reward companies showing tangible revenue, not just spend. CNBC ↗
INDUSTRIALS
Caterpillar cited strong demand tied to the AI data-center buildout and guided tariff costs to the low end of its range — a read-through that infrastructure capex is cushioning trade-policy risk. FFT ↗
HEALTHCARE
Beyond Curium/Lantheus and KKR/Integer, a separate AstraZeneca megamerger was blocked — a reminder that antitrust scrutiny still gates the largest pharma tie-ups even as mid-caps consolidate freely. MarketScale ↗
M&A / LEVERAGED FINANCE
Three healthcare deals worth $14B+ in a single day, plus record equity highs, point to a re-accelerating M&A tape — sponsors (KKR, AE Industrial) remain aggressive and credit is open. The split screen: mid-cap deals sail through while megamergers (AstraZeneca) hit regulatory walls, steering activity toward $5–10B "sweet spot" transactions. MarketScale ↗
MARKET TONE
Record highs. The Dow, S&P 500 (7,700+) and Nasdaq (26,500+) all printed all-time highs early in the week on strong earnings breadth. CNBC ↗
Earnings beat rate. 84%+ of reporting S&P 500 companies topped estimates — an unusually strong season underpinning the rally. FFT ↗
Tariffs land. A new schedule with rates from 10% to 40%+ took effect August 7 — watch for margin and supply-chain commentary in coming guidance. FFT ↗
Fed steady. Rates held at 3.50–3.75%; the FOMC still flags elevated inflation partly from energy supply shocks, keeping cuts uncertain. Corbett Road ↗
Deal momentum. A $14B+ healthcare-M&A Monday signals sponsors and strategics are leaning back in — a constructive sign for banking pipelines. MarketScale ↗
INTERVIEW ANGLE
TOPIC: WHY DEAL SIZE SHAPES REGULATORY RISK
This week's split — two mid-cap healthcare deals cleared while an AstraZeneca megamerger was blocked — is a sharp way to show you think about deal risk, not just price. Antitrust review scales with market concentration, so the same sector can be wide open for $5–8B deals and closed for the biggest combinations.
Why mid-caps clear: KKR/Integer (a supplier) and Curium/Lantheus add scale without creating a dominant share in any single product market, so regulators are less likely to object.
Why megamergers stall: combining two leaders can concentrate a therapeutic area, triggering blocks or heavy divestiture demands.
What bankers do about it: price in a "regulatory discount," negotiate reverse break-up fees, and pre-plan divestitures — antitrust risk directly affects offer price and certainty of close.
How to bring it up: "What struck me this week was the contrast — Curium/Lantheus and KKR/Integer went through, but a bigger AstraZeneca merger got blocked. It's a good reminder that in M&A, deal size and market concentration drive regulatory risk, and that risk shows up in price and break-up fees, not just the strategic logic."